Blood Test Could Predict Dementia Risk in Women Decades Before Symptoms

A groundbreaking study from the University of California San Diego has revealed that a simple blood test could detect a woman’s risk of developing dementia up to 25 years before symptoms appear, potentially revolutionizing early intervention strategies.

Researchers analyzed blood samples from 2,766 women aged 65 to 79 who participated in the Women’s Health Initiative Memory Study during the late 1990s. At the beginning of the study, all participants showed no signs of cognitive impairment. After following these women for up to a quarter-century, scientists discovered a compelling connection between a specific biomarker protein and future dementia risk.

The study, published in JAMA Network Open, found that the biomarker phosphorylated tau 217 (p-tau217) was “strongly associated” with the future development of mild cognitive impairment and dementia. Women with elevated levels of p-tau217 at the study’s outset were significantly more likely to develop cognitive decline years later.

“The key takeaway is that our study suggests it may be possible to detect risk of dementia two decades in advance using a simple blood test in older women,” explained lead author Aladdin H. Shadyab, PhD, an associate professor of public health and medicine at UC San Diego.

This extended lead time could transform dementia prevention and treatment approaches by allowing for earlier intervention strategies well before memory problems affect daily functioning.

The research also revealed important nuances in how the biomarker predicts risk across different populations. Women over 70 with higher p-tau217 levels showed poorer cognitive outcomes compared to those under 70. Similarly, women carrying the APOE ε4 gene, a known Alzheimer’s risk factor, demonstrated a stronger connection between elevated biomarker levels and future cognitive decline.

Interestingly, the study uncovered that p-tau217 was a more potent predictor of dementia in women who received estrogen and progestin hormone therapy compared to those given a placebo, suggesting complex interactions between hormones and dementia pathways.

“Blood-based biomarkers like p-tau217 are especially promising because they are far less invasive and potentially more accessible than brain imaging or spinal fluid tests,” noted senior author Linda K. McEvoy, PhD, senior investigator at Kaiser Permanente Washington Health Research Institute and professor emeritus at the Herbert Wertheim School of Public Health.

This accessibility could democratize early detection efforts and accelerate research into dementia risk factors and prevention strategies.

Despite these promising findings, the researchers caution that blood tests for Alzheimer’s disease remain in the investigational stage and are not yet recommended for routine screening of asymptomatic individuals. Additional research is needed before such approaches can be implemented in clinical settings.

The study’s limitations include its focus exclusively on older women, meaning the results may not apply equally to men or younger populations. Additionally, the researchers examined overall dementia outcomes rather than specific subtypes like Alzheimer’s disease.

Future research will need to explore how various factors—including genetics, hormone therapy, and age-related medical conditions—interact with plasma p-tau217 levels to influence dementia risk. Such investigations could further refine our understanding of who might benefit most from early screening and intervention.

As dementia rates continue to rise globally with an aging population, this research represents a significant step toward earlier detection and potentially more effective management of a condition that currently affects millions worldwide.